# A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

> **NCT02879669** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Targovax Oy** · enrollment: 31 (actual)

## Conditions studied

- To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy

## Interventions

- **BIOLOGICAL:** ONCOS-102
- **DRUG:** Pemetrexed/cisplatin (carboplatin)
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02879669
- **Lead sponsor:** Targovax Oy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2020-05
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02879669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02879669, "A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02879669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*